Table 3 The relationship between clinico-pathological characteristics of patients with ER negative primary operable invasive ductal breast cancer and cancer- specific survival

Age (<50/>50 years)

0.78 (0.42-1.47

0.448

Size (≤20/21-50/>50 mm)

2.19 (1.14-4.22)

0.018

0.116

Grade (I/II/III)

1.30 (0.63-2.72)

0.478

Involved lymph node (0/1-3/>3)

1.85 (1.24-2.66)

0.001

1.71 (1.17-2.50)

0.006

Progesterone -receptor status (PR-/PR+)

0.05 (0.00-22.73)

0.330

HER-2 status (HER-2 -/HER-2+)

1.26 (0.66-2.41)

0.489

Ki-67 status (Low Ki-67/High Ki-67)

1.48 (0.70-3.11)

0.305

LVI (Absent/Present)

2.14 (1.08-4.22)

0.029

0.428

MVD (CD34+) (tertiles 1, 2, 3)

1.62 (1.08-2.44)

0.021

0.130

Loco-regional treatment (Lumpectomy + radiotherapy/mastectomy + radiotherapy)

3.27 (1.44-7.42)

0.005

2.64 (1.14-6.09)

0.023

Systemic treatment (ER-based treatment) (hormonal/hormonal + chemotherapy/chemotherapy/none)

1.00 (0.70-1.42)

1.00